Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000807019 | SCV000947045 | likely benign | Noonan syndrome 9 | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002282373 | SCV002572237 | likely benign | not specified | 2022-08-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004994025 | SCV005509572 | uncertain significance | Cardiovascular phenotype | 2024-09-26 | criteria provided, single submitter | clinical testing | The c.2261G>A (p.S754N) alteration is located in exon 14 (coding exon 14) of the SOS2 gene. This alteration results from a G to A substitution at nucleotide position 2261, causing the serine (S) at amino acid position 754 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Service de Génétique Moléculaire, |
RCV001261124 | SCV001438531 | likely benign | Noonan syndrome | no assertion criteria provided | clinical testing |